SERENTIL
LOE ApproachingNDAORALTABLET
Approved
Feb 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SERENTIL is an oral small-molecule tablet approved in 1970 by Novartis for an unspecified indication. The mechanism of action and pharmacologic class are not documented in available records.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30); brand team likely in transition mode with reduced headcount expectations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring; SERENTIL is a legacy mature product with declining commercial opportunity. Assignment to this product typically represents a caretaker or transition role rather than a growth position.
Brand ManagerField Sales Representative
Worked on SERENTIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.